• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

maryann.anderson@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-3515-0215

A/Prof Mary Ann Anderson

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

177 Scholarly works
1 Projects

HIGHLIGHTS

  • 2022

    Journal article

    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
    DOI: 10.1182/blood.2022016040
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2022

    Research grants (other domestic)

    Novel Strategies to Predict and Monitor Response to CAR T-Cell Therapy in DLBCL
  • 2021

    Journal article

    Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
    DOI: 10.1182/bloodadvances.2021005083
  • 2021

    Journal article

    Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
    DOI: 10.1182/blood.2020009578
  • 2020

    Journal article

    BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
    DOI: 10.1182/blood-2020-137775
  • 2020

    Journal article

    Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
    DOI: 10.1182/BLOOD.2019004205
Mary Ann Anderson

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Venetoclax Retreatment in Chronic Lymphocytic Leukemia is biologically rational and clinically effective.
    DOI: 10.1182/bloodadvances.2026019871
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
    DOI: 10.1182/bloodadvances.2025015986
  • 2026

    Journal article

    Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL
    DOI: 10.1182/bloodadvances.2025017755
  • 2026

    Journal article

    Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
    DOI: 10.1200/JCO-25-01695
  • 2026

    Journal article

    Neurological implications of chimeric antigen receptor-T cell therapy
    DOI: 10.1136/bmjno-2025-001491
  • 2025

    Journal article

    Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial
    DOI: 10.1093/infdis/jiaf297
  • 2025

    Journal article

    Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia
    DOI: 10.1002/hem3.70284

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224